Peptide Profile: VIP5 is described as a modified form of vasoactive intestinal peptide (VIP), a 28–amino-acid neuropeptide produced in the gut, brain, lungs, and immune system. VIP signaling promotes vasodilation, smooth-muscle relaxation, bronchodilation, and anti-inflammatory immune modulation, and is being studied in conditions such as chronic inflammatory response syndromes and respiratory disease. VIP5 is an investigational analogue; any practical dosing is extrapolated from VIP nasal or injectable protocols and must remain research-only under medical supervision.
VIP5 Dosing Protocol (Educational Example Only)
Adapted from published VIP nasal-spray protocols and compounding-pharmacy guidance; specific data for VIP5 are not available. This is not a prescription or medical advice.
| Phase | Time frame | Male dosing (example) | Female dosing (example) | Administration & schedule | Monitoring / goals |
|---|---|---|---|---|---|
| Baseline evaluation | 2–4 weeks before start | No VIP5. Take full history and exam; labs: CBC, CMP, fasting glucose, lipids, inflammatory markers as indicated; review all meds and supplements. | Same as males; include pregnancy test where appropriate and review contraception or plans for pregnancy. | N/A | Confirm VIP-type therapy is appropriate in a supervised research/clinical setting. Exclude uncontrolled asthma, severe hypotension, active GI bleeding, or unexplained chronic diarrhea that could worsen with VIP-like vasodilation and secretory effects. |
| Initiation (low dose) | Weeks 1–2 | 50 mcg once daily intranasal (one spray delivering 50 mcg) or equivalent SQ dose, preferably in the morning. | Same dose and schedule; VIP-type dosing is not sex-based. Frail or very low-weight patients may remain at 25–50 mcg as directed by clinician. | Use compounded solution (e.g., 50 mcg per spray). Keep refrigerated; alternate nostrils; avoid blowing nose immediately after dosing. For SQ use insulin syringe and rotate sites. | Goal is tolerance, not big symptom shifts. Track blood pressure, heart rate, headache, flushing, nasal irritation, bowel habit changes, and sleep. Any marked dizziness or diarrhea → pause or reduce dose. |
| Early titration | Weeks 3–4 | Increase to 50 mcg twice daily (100 mcg/day) if well tolerated; many VIP protocols step up after 1–2 weeks. | Same as males. | Morning and late-afternoon dosing; keep at least 4–6 hours between sprays. SQ users can mirror the same schedule. | Begin evaluating desired effects (energy, cognitive clarity, reduced inflammatory flares, improved breathing or GI comfort) while watching for hypotension or loose stools. Re-check vitals and review symptom log at the end of week 4. |
| Structured escalation | Weeks 5–8 | If still tolerated and more benefit needed, increase toward 200 mcg/day, for example 50 mcg four times daily or 100 mcg twice daily, according to prescriber preference. | Same daily ranges; escalation speed individualized but not routinely different for sex. | Keep dosing evenly spaced through the day. For nasal use, continue alternating nostrils and prime the pump as instructed after periods of non-use. | Identify the lowest effective total daily dose that improves target outcomes without troublesome side effects. Repeat labs (basic metabolic panel, inflammatory markers if relevant) about once per month during escalation. |
| Maintenance cycle | Months 3–4 (or 3–6) | Maintain at the individualized effective dose, typically 100–200 mcg/day; some supervised protocols may explore higher totals in refractory cases, but evidence is limited. | Same maintenance range. Women who are pregnant, breastfeeding, or trying to conceive should discontinue and discuss alternatives. | Keep a consistent schedule; avoid unsupervised frequent up-and-down changes. Many clinicians cycle VIP-type therapy for 8–12 weeks, sometimes up to 16, followed by 4–8 weeks off. | Reassess symptoms, quality of life, and objective markers (blood pressure, lab trends) every 4–8 weeks. If benefit plateaus or side effects rise, first attempt dose reduction before considering discontinuation. |
| Taper / off-cycle | 2–4 weeks | Reduce to half the maintenance dose for 1–2 weeks, then decrease to once-daily for another week before stopping. | Same taper strategy. | Either lower per-spray frequency (e.g., four times daily → twice daily → once daily) or reduce mcg per dose, depending on pharmacy formulation. | Watch for return or rebound of baseline symptoms. Use off-cycle to reconsider whether another VIP5 cycle is justified or whether alternative therapies and lifestyle strategies should be prioritized. |
Safety notes
VIP5, like other VIP analogues and variants (VIP1–VIP8), is still at the experimental or patent stage, with human clinical data based on native VIP or closely related agonists rather than VIP5 specifically. Long-term safety, ideal dose, and interaction profile remain uncertain. Use only under the direction of a licensed clinician experienced with peptide therapies; never self-source or self-dose research peptides.
References
https://superpower.com/rx-info/vip-nasal-spray
https://superpower.com/informed-medical-consent/vip-nasal-spray
https://www.survivingmold.com/save-vip/support-for-use-of-vip-in-seid
https://static.spacecrafted.com/e0b93e6917ff4e6c9be115e1e4206569/r/e9553969e3944088914e5de6cb15d7af/1/VIP%20Spray%20Patient%20instructions.pdf
https://www.strivepharmacy.com/medications/vasoactive-intestinal-peptide-vip-nasal-spray
https://pdlabsrx.com/vasoactive-intestinal-peptide-vip
https://pmc.ncbi.nlm.nih.gov/articles/PMC3738270/
https://data.epo.org/publication-server/rest/v1.0/publication-dates/20230308/patents/EP4144847NWA1/document.pdf
VIP5 peptide profile overview, uses, sample dosing protocol, educational only, not medical advice content.
VIP5, VIP5 peptide, VIP5 peptide profile, VIP5 dosing, VIP5 protocol, VIP5 nasal spray, vasoactive intestinal peptide, VIP peptide, VIP analogue, peptide profile VIP5, peptide protocol, peptide dosing chart, male VIP5 dosing, female VIP5 dosing, peptide therapy, peptide research, experimental peptide, anti-inflammatory peptide, immune modulation, neuropeptide, gut peptide, vascular peptide, bronchodilation, vasodilation, chronic inflammation, CIRS, respiratory health, metabolic health, gut health, brain health, peptide wellness, integrative medicine, functional medicine, peptide clinic, peptide cycle, peptide titration, peptide safety, peptide side effects, VIP5 benefits, VIP5 risks, VIP5 guidance, VIP5 education, VIP5 peptide use, VIP5 overview, VIP5 treatment, VIP5 support, VIP5 mechanism, VIP5 science, VIP5 results, VIP5 review.
